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Despite the enormous morbidity attributed to schistosomiasis, there is still no vaccine to
combat the disease for the hundreds of millions of infected people. The anthelmintic drug,
praziquantel, is the mainstay treatment option, although its molecular mechanism of
action remains poorly defined. Praziquantel treatment damages the outermost surface of
the parasite, the tegument, liberating surface antigens from dying worms that invoke a
robust immune response which in some subjects results in immunologic resistance to
reinfection. Herein we term this phenomenon Drug-Induced Vaccination (DIV). To identify
the antigenic targets of DIV antibodies in urogenital schistosomiasis, we constructed a
recombinant proteome array consisting of approximately 1,000 proteins informed by
various secretome datasets including validated proteomes and bioinformatic predictions.
Arrays were screened with sera from human subjects treated with praziquantel and
shown 18 months later to be either reinfected (chronically infected subjects, CI) or
resistant to reinfection (DIV). IgG responses to numerous antigens were significantly
elevated in DIV compared to CI subjects, and indeed IgG responses to some antigens
were completely undetectable in CI subjects but robustly recognized by DIV subjects. One
antigen in particular, a cystatin cysteine protease inhibitor stood out as a unique target of
DIV IgG, so recombinant cystatin was produced, and its vaccine efficacy assessed in a
heterologous Schistosoma mansoni mouse challenge model. While there was no
significant impact of vaccination with adjuvanted cystatin on adult worm numbers,
highly significant reductions in liver egg burdens (45-55%, P<0.0001) and intestinal egg
burdens (50-54%, P<0.0003) were achieved in mice vaccinated with cystatin in two
independent trials. This study has revealed numerous antigens that are targets of DIVorg May 2021 | Volume 12 | Article 6630411
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Frontiers in Immunology | www.frontiersin.antibodies in urogenital schistosomiasis and offer promise as subunit vaccine targets for a
drug-linked vaccination approach to controlling schistosomiasis.Keywords: cystatin, praziquantel, proteome microarray, urogenital schistosomiasis, vaccine, immunomicsINTRODUCTION
Schistosomiasis is a chronic, often debilitating, parasitic disease
afflicting over 250 million people worldwide and is responsible
for the loss of approximately 1.9 million disability adjusted life
years (DALYs) (1). Three schistosome species - Schistosoma
mansoni, S. haematobium and S. japonicum - account for
almost all human infections. Adult S. mansoni and S.
japonicum live in the portal and mesenteric veins while S.
haematobium lives in the veins of the bladder, where the male
and female flukes pair and survive for many years, producing
hundreds of fertilized eggs per day. Severe morbidity results from
host immune responses to eggs in tissues, and includes periportal
fibrosis, portal hypertension, urinary obstruction, and bladder
carcinoma. Currently, chemotherapy with praziquantel (PZQ) is
the preferred treatment for schistosomiasis, although control
programs based on mass drug administration/preventative
chemotherapy are complicated by rapid and frequent re-
infection and the difficulties and expense of maintaining these
programs over a long term (2).
PZQ is widely used to treat human schistosome infections
and has two main effects on the parasites – rapid paralysis and
tegument damage. Experimental work in mice has demonstrated
that PZQ treatment exposes tegumental (surface membrane)
antigens (3). In addition, adult worms are believed to suppress
schistosome-specific immune responses so that worm death
results in increased responsiveness to schistosome antigens (4).
The interaction of PZQ with schistosomes results in a
quantitative and qualitative alteration of host–parasite-
specific immune responses . Ear ly studies reported
modifications in the cell proliferative responses (4) and in the
levels and types of antibody (5, 6) and cytokine responses (7)
following treatment. While this infection and treatment
approach to inducing immunologic resistance to reinfection
has been well articulated (8), the antigen targets of protective
immune responses in human subjects is poorly understood. We
refer to this phenomenon herein as “Drug Induced Vaccination
(DIV)”. Very few schistosomiasis vaccine candidates have
progressed towards commercial development (9), and none of
those antigens in development were identified using a DIV-based
strategy. Innovative approaches are therefore needed to identify
the protective schistosome proteins that are the target of DIV,
and develop them into a subunit vaccine.
An “immunome” can be defined as the entire set of antigens
or epitopes that interface with a host immune system. Recent
advances in high order multiplexing, often referred to as
megaplexing, provide a practical, high throughput, and
affordable approach to estimating the immunomic profiles of a
human or animal to a pathogen (10, 11). The advantage of the
systems biology approach is that it aims to look at the totality oforg 2the humoral immune response to an infectious disease,
attempting to be as complete and accurate as possible (12). It
takes advantage of genomics to design primers to amplify and
clone each annotated gene from dozens of infectious agents,
enabling the expression of thousands of proteins on a genome-
wide scale. This approach permits investigators to assess the
repertoire of antibodies and can be used to perform large-scale
analyses to determine whole profiles of reactive antigens and
patient-to-patient and species-dependent differences in the
response to infection while empowering statistical conclusions.
We applied protein array technology for the first time to study
the immune response to a eukaryotic pathogen (S. mansoni),
with the creation of the first schistosome protein array which
contained a small representative subset of S. mansoni and S.
japonicum surface proteins (10). A subsequent study screened
this array with a small number of serum samples from human
subjects infected with S. haematobium who had been treated
with a single dose of 40 mg/kg PZQ and either became reinfected
or developed DIV (13). While a valuable study that revealed new
and previously known vaccine candidate antigens, major
limitations were the small number of arrayed antigens and the
cross-species nature of the study – i.e., select S. mansoni and S.
japonicum arrayed antigens probed with sera from S.
haematobium infected individuals.
Herein we describe the construction of a S. haematobium
protein microarray consisting of almost 1,000 feature proteins
(selected by a multi-omics approach consisting of proteomics,
transcriptomics, and bioinformatics), probing of that array to
identify targets of DIV and validation of the vaccine efficacy of
the top-ranking antigen target in a murine model
of schistosomiasis.MATERIALS AND METHODS
Ethical Statement, Study Design
and Cohorts
Ethical approval for sample collection from human subjects in
Zimbabwe was obtained by the Medical Research Council of
Zimbabwe. The demographics of the study population has been
described in depth elsewhere (13), but briefly, study participants
were residents of a S. haematobium-endemic rural village in
Murewa in the Mashonaland East Province of Zimbabwe. The
village has little or no infection with soil-transmitted helminths and
a low S. mansoni prevalence (<2%). Serum samples were provided
from a cohort of S. haematobium-infected individuals (n = 106)
aged 5–14 years who had never been treated with PZQ prior to this
study and were free from co-infection with other helminths,
Plasmodium, and HIV. At the start of the study (baseline),
subjects who were positive for S. haematobium eggs (at least oneMay 2021 | Volume 12 | Article 663041
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separate day) following urinalysis were treated with PZQ by weight
(40 mg/kg) and then assessed by urinalysis at 6 weeks to confirm
clearance of the infection (no eggs found in any of three urine
samples, each collected on a separate day). Individuals were
followed for 18 months and maintained regular water contact
throughout this period. Subjects were assessed for infectivity with
S. haematobium at 6months and at the end of the study. Individuals
who were egg-positive at 18 months post-treatment (n = 32) were
deemed CI and those who were egg-negative (n = 74) were
categorized as DIV. Serum samples were obtained from both 0-
and 18-month timepoints. For this study, we selected a subset of
subjects as follows: CI subjects that had the highest post-treatment
egg burdens (eggs/10 ml 10–104; n = 13) and DIV subjects that had
some of the highest egg burdens at baseline (eggs/10 ml 44–743; n =
16), reasoning that these individuals represented extremities of the
DIV and CI spectrums and therefore would maximize the
likelihood of identifying differences in antibody signatures
between CIs and DIVs.
On collection, all serum and urine samples were stratified
based on egg burden as determined by microscopy analysis of
urine samples (high, ≥50 eggs per 10 ml urine; or light, 1-49 eggs
per 10 ml urine).
S. haematobium Protein Array Feature
Selection and Construction
Protein selection criteria for inclusion in the S. haematobium
protein array was the presence of the protein in surface or
secreted proteome data sets. Accordingly, proteins in adult S.
haematobium tegument, adult soluble excretory/secretory
products (ES) (14) and extracellular vesicles (EVs) (15), egg ES
and soluble egg antigen (SEA) (14), and S. haematobium
orthologues of S. mansoni schistosomula tegument proteins (16)
(650 proteins in total) were selected for printing on the array. The
remaining ~350 proteins were S. haematobium orthologues of
proteins printed on a S. mansoni second generation array (17).
The list of sequences selected for inclusion in the array can be
accessed throughMendeley Data at the following link: doi:10.17632/
6c4bzj9nzr.1. Open reading frames with predicted signal peptides
removed were flanked by 20 bp sequences corresponding to pXI
recombination sites (18) were codon optimised for expression in E.
coli and commercially synthesised and cloned in pUC57 by either
Twist Bioscience (sequences < 1.8 kb) or ProteinCT (sequences >
1.8 kb). Synthesised genes were amplified by PCR using
oligonucleotides corresponding to the pXI recombination sites
and cloned into pXI, in-frame with the sequences encoding the 5’
HA and 3’ HIS tags using in vivo recombination (19). Plasmid
minipreps were produced and proteins encoded by each purified
plasmid were expressed in vitro (RTS 100 E. coli HY kit – 5 Prime,
MD, USA) according to themanufacturer’s instructions and printed
onto 8-pad nitrocellulose-coated AVID glass slides (Grace Biolabs,
Bend, OR, USA) with an Omnigrid 100 microarray printer
(Genomic Solutions, Ann Arbor, MI, USA). Vector without insert
was similarly produced and printed (in multiple locations) as a
negative control. Multiple empty spots were left on each pad to serve
as background controls. Purified human IgG, anti-human IgG andFrontiers in Immunology | www.frontiersin.org 3schistosome extracts (S. haematobium adult- and egg-stage ES
products, soluble egg antigen and adult-stage tritonX-100-soluble
extract) were also printed as positive controls. Expression quality
control was assessed by detection of N-terminal HA and C-terminal
HIS tags as previously described (18).
Probing of Protein Arrays With
Human Sera
IgG responses to antigens on the array were determined by
probing with human serum (1:50 in array blocking buffer/10% E.
coli lysate) as previously described (18) with the exception that
anti-human IgG-Qdot (1:100 in array blocking buffer) was used
as the secondary antibody.
Data Analysis and Bioinformatics
After subtracting the background from each slide, the signal
intensity (SI) of each spot was corrected using the “group
average” method, where the mean SI of the negative control
(empty vector) spots were subtracted from the SI of each protein
spot. Corrected SIs were transformed using variance stabilizing
normalization (vsn) in GMine (http://cgenome.net/gmine) using
the VSN Bioconductor package (20). A reactivity cut-off of 543
(calculated as the mean plus 1.5 standard deviations (SD) of the
SI of the negative control spots) was used. Significance
differences between antibody responses in DIV versus CI
groups were determined by Student’s t-test and p values
adjusted for multiple statistical comparisons.
Recombinant Protein Production in E. coli
The top ranked IgG response in terms of highest-fold change in SI
between DIV and CI subjects targetedMS3_01693, a cystatin family
member. The S. mansoni homolog of MS3_01693 (smp_034420)
was selected for recombinant expression and validation in our
vaccine model (S. mansoni) as numbers of S. haematobium
cercariae were insufficient to perform appropriately powered
vaccination trials using an S. haematobium model of infection.
The ORF was synthesized by Genscript and contained flanking
NdeI and XhoI sites to accommodate cloning into the pET41a
expression vector (Novagen) such that the N-terminal GST tag was
removed but the C-terminal 6-His tag was retained. Protein
expression was induced for 24 h in E. coli BL21(DE3) by addition
of 1 mM isopropyl beta-D-thiogalactopyranoside (IPTG) using
standard methods. Recombinant MS3_01693 required 8M urea to
solubilize and was prepared and purified using a method described
by us elsewhere (21). The final concentration of purified
recombinant protein was adjusted to 1 mg/ml and aliquots were
stored at -80°C.
Vaccine Formulation and Immunization
Regimen
Vaccine experiments were performed using an S. mansoni challenge
model as recently described by us (21). Briefly, two groups of 10
BALB/c mice (6–8 weeks) were immunized intraperitoneally on day
1 with either recombinant S. mansoni smp_034420 (cystatin) or
recombinant E. coli thioredoxin (TrX) expressed and purified in
identical fashion as an irrelevant control protein (50 mg/mouse).May 2021 | Volume 12 | Article 663041
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adjuvant (Thermofisher) and 5 mg of CpG ODN1826 (InvivoGen).
Two booster immunizations (for a total of three immunizations)
were administered on days 15 and 29 and each mouse was
challenged by tail penetration with 120 S. mansoni cercariae on
day 43. Blood was collected by tail bleed at day 42 to determine pre-
challenge antibody titres. Two independent trials were performed.Necropsy and Estimation of Parasite
Burden
Necropsy and quantification of parasite burdens was performed as
described elsewhere (21). Mice were necropsied at day 91 (7 weeks
post-infection) and blood was collected by cardiac puncture. Adult S.
mansoni flukes were harvested by vascular perfusion and counted.
Livers were removed, weighed, and digested, and schistosome eggs
were concentrated by centrifugation at 1,000 g for 10 min and re-
suspended in 10% formalin. The number of eggs in a 5 mL aliquot was
counted in triplicate and the number of eggs per gram (EPG) of liver
tissue was calculated. Small intestines were removed and cleaned of
debris before being weighed and digested as per the livers. Eggs were
similarly concentrated and counted to calculate intestinal EPG.
Statistics
All statistics were performed using GraphPad Prism 9.0. The
reductions in worm and egg numbers were analysed using a
Student’s t-test and results were expressed as the mean ±
standard error of the mean. For antibody titers, the reactivity cut-
off values were determined as themean + 3SD of the values obtained
with naive serum.Frontiers in Immunology | www.frontiersin.org 4RESULTS
S. haematobium Secreted Proteome Array
Proteome arrays were probed with monoclonal antibodies raised
to the N-terminal HA tag to assess the percentage of proteins
expressed and C-terminal His tag to determine the percentage of
full-length protein expression from all 992 arrayed antigens. In
total, 929 proteins were expressed (Figure 1A), and 863 (93%) of
those were full-length (Figure 1B). Eighty-nine of the proteins
selected for printing contained a predicted signal peptide (Table
S1). We expect the true number to be higher than this due to the
draft nature of the genome and consequently incomplete ORFs.
Immunoreactivity of Arrayed Proteins
A total of 138 proteins were targets of significantly (P<0.05)
elevated SIs (IgG responses) in DIV subjects 18 months after
PZQ treatment compared to baseline (Table S2 and Figure 2).
Fold-changes ranged from 2-3,210 and reactive proteins were
sourced from various tissue proteomes (Figure S1; adult ES,
extracellular vesicle, tegument, and soluble egg antigen) as well as
from bioinformatic predictions. The top 15 antigens ranked by SI
after PZQ treatment are provided in Table 1 and Figure 3. Some
proteins were immunoreactive at baseline but were the targets of
elevated responses after PZQ, including the microexon gene
family member MEG-8 (9-fold increase in SI) and cathepsin B
(5-fold increase), whereas others were not recognized or
recognized weakly at baseline but then strongly after PZQ
treatment, such as synaptotagmin (130-fold increase) and
trematode eggshell synthesis domain containing protein (38-
fold increase). Only one protein, cystatin (MS3_01693), wasA
B
FIGURE 1 | Quality control probe of the S. haematobium protein microarray. Arrays were probed with (A) anti-hemagglutinin (HA) antibody to detect expression of
the N-terminal HA tag and determine the percentage of protein expression from all arrayed antigens, and (B) anti-6-HIS antibody to detect expression of the
C-terminal 6-HIS tag and determine the percentage of full-length protein expression from all arrayed antigens. No DNA refers to control spots where plasmid DNA
(encoding genes to be expressed) is omitted from the reverse transcription-translational products printed at those locations. Sh Adult ES, S. haematobium adult fluke
Excretory/Secretory products; Sh Adult PBS extract, S. haematobium adult fluke PBS-soluble somatic extract; Sh egg ES, S. haematobium egg ES products; Sh
Adult triton extract, S. haematobium adult fluke TritonX-114-soluble extract; Sh SEA, S. haematobium soluble egg antigen.May 2021 | Volume 12 | Article 663041
Pearson et al. Urogenital Schistosomiasis VaccinomicsFIGURE 2 | Approach to identification of antigenic targets of DIV. Antigens which were targets of IgG responses that were significantly elevated 18 months after PZQ
treatment compared to before treatment in DIV subjects (1, upper left panel), and significantly elevated in DIV subjects compared to CI subjects 18 months after PZQ




Description SI before treatment2 SI after treatment3 Fold change4 P value6 Selection method
for array inclusion7
MS3_07738 MEG-8 family 213.839 1995.197 9.330 0.004 bioinformatic
MS3_02690 synaptotagmin 14.729 1916.206 130.096 0.039 proteomic (T)
MS3_06745 eukaryotic translation
elongation factor 1 beta 2
304.375 1874.503 6.159 0.014 proteomic (AES)
MS3_08159 trematode eggshell synthesis
domain containing protein
44.755 1687.919 37.714 0.010 bioinformatic
MS3_01775 putative DNA-binding protein 45.404 1520.667 33.492 0.013 bioinformatic
MS3_03054 chaperonin containing TCP1,
subunit 5 (epsilon)
247.255 1516.008 6.131 0.003 proteomic (SEA)
MS3_09161 thymidylate kinase 221.841 1492.275 6.727 0.023 proteomic (AES)
MS3_01938 proliferating cell nuclear antigen 358.357 1445.483 4.034 0.012 bioinformatic
MS3_10116 60S ribosomal protein L23 238.344 1427.153 5.988 0.007 bioinformatic
MS3_10687 cathepsin B-like cysteine
proteinase




110.807 1380.553 12.459 0.006 proteomic (SEA)
MS3_04962 interferon-related
developmental regulator 1
389.531 1365.497 3.505 0.042 bioinformatic
MS3_01693 cystatin 0.000 1365.483 n/a5 0.007 bioinformatic
MS3_08717 NADH dehydrogenase 1 alpha
subcomplex subunit 13
264.685 1363.492 5.151 0.014 bioinformatic
MS3_02176 microsomal glutathione S-
transferase 3
94.896 1362.997 14.363 0.001 proteomic (T)Frontiers in Immunology | www.frontiersin.org 5 May 2021 | Volum1WormBase ParaSite online database, version 14 https://parasite.wormbase.org/Schistosoma_haematobium_prjna78265/Info/Index/.
2mean signal intensity of DV cohort before PZQ treatment.
3mean signal intensity of DIV cohort 18 months after PZQ treatment.
4fold change in mean signal intensity of DIV cohort 18 months after PZQ treatment compared to DIV cohort before treatment.
5n/a = not assessed; fold change unable to be calculated due to mean signal intensity of CI cohort below the reactivity threshold.
6significance of difference in mean signal intensity of DIV cohort 18 months after PZQ treatment compared to DIV cohort before treatment.
7proteins for array inclusion selected from bioinformatic analysis of second-generation S. mansoni array (16) or analysis of S. haematobium proteomes (13, 14).
T, S. haematobium adult tegument, AES, S. haematobium adult excretory/secretory products, SEA, S. haematobium soluble egg antigen.e 12 | Article 663041
Pearson et al. Urogenital Schistosomiasis VaccinomicsTABLE 2 | Antigens which are the targets of significantly higher IgG responses in DIV, compared to CI, subjects 18 months after PZQ treatment.
Antigen (WBPS141
Accession)
Description CI cohort SI2 DIV cohort SI3 Fold change4 P value5 Selection
method for array
inclusion6
MS3_01693 cystatin 36.769 1365.483 37.137 0.030 bioinformatic
MS3_02176 microsomal glutathione S-transferase 3 495.452 1362.997 2.751 0.027 proteomic (T)
MS3_01105 universal stress protein 35.769 1214.122 33.943 0.030 proteomic (AES)
MS3_06126 sulfide quinone reductase, putative 114.734 1035.405 9.024 0.002 bioinformatic
MS3_07195 ribosomal protein S11 118.385 1000.316 8.450 0.026 bioinformatic
MS3_07763 succinyl-CoA ligase subunit beta,
mitochondrial
107.417 958.094 8.919 0.045 proteomic (SEA)
MS3_05425 14 kDa subunit splicing factor 3b 123.558 934.925 7.567 0.050 proteomic (AES)
MS3_08689 synaptic vesicle membrane protein VAT-1-
like protein
206.939 918.716 4.440 0.046 bioinformatic
MS3_06283 dexamethasone-induced Ras-related
protein 1
156.625 875.308 5.589 0.024 bioinformatic
MS3_04279 saposin B domain-containing protein 68.077 822.758 12.086 0.047 bioinformatic/EV
homologue
MS3_01972 leptin receptor overlapping transcript-like 1 77.240 768.733 9.952 0.004 proteomic (SEA)
MS3_00257 regulator of microtubule dynamics protein 1 77.878 697.027 8.950 0.045 bioinformaticFrontiers in Immunology | www.frontiersin.org 6 May 2021 | Volume 11WormBase ParaSite online database, version 14 https://parasite.wormbase.org/Schistosoma_haematobium_prjna78265/Info/Index/.
2mean signal intensity of CI cohort 18 month after PZQ treatment.
3mean signal intensity of DIV cohort 18 months after PZQ treatment.
4fold change in mean signal intensity of CI cohort compared to DIV cohort 18 months after PZQ treatment.
5significance of difference in mean signal intensity of CI cohort compared to DIV cohort 18 months after PZQ treatment.
6proteins for array inclusion selected from bioinformatic analysis of second-generation S. mansoni array (16) or analysis of S. haematobium proteomes (13, 14).
T, S. haematobium adult tegument, AES, S. haematobium adult excretory/secretory products, SEA, S. haematobium soluble egg antigen.FIGURE 3 | Antibody signatures to arrayed antigens differ in S. haematobium-infected subjects before and after PZQ treatment. Graph showing antigens which are
targets of the top 15 significant (sorted by signal intensity) IgG responses in the DIV cohort before and after PZQ treatment. The dashed line represents the reactivity
cut-off, determined as the mean SI + 1.5SD of the IgG response to all negative control (empty vector) spots. Significance was determined using a Mann-Whitney
test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.2 | Article 663041
Pearson et al. Urogenital Schistosomiasis Vaccinomicscompletely unrecognized by IgG at baseline (SI = 0) but strongly
recognized after PZQ treatment.
We also compared immunoreactive proteomes between DIV
and CI subjects 18 months after PZQ treatment (Figure 2).
Twelve proteins were significantly more reactive in the DIV
cohort after PZQ treatment, 9 of which were also significantly
more reactive in the DIV cohort at 18 months post-treatment
compared to the CI cohort 18 months post-treatment (Table 2
and Figure 4). Cystatin (MS3_01693) was the target of the
greatest fold-change (37-fold increase; P=0.030) in IgG
reactivity after PZQ treatment. The percent identity across
overlapping regions between S. haematobium and S. mansoni
cystatins is 86%. S. haematobium cystatin contains a 12 amino
acid predicted insertion that is not present in either S. mansoni or
S. japonicum cystatins (Figure S2).
Vaccination of Mice With Recombinant
S. mansoni Cystatin Significantly Reduces
Egg Output in a S. mansoni Challenge Model
The mouse model of S. haematobium is sub-optimal, with large
numbers of challenge cercariae required to get relatively lowFrontiers in Immunology | www.frontiersin.org 7numbers of adult flukes. Moreover, unlike in humans, adult S.
haematobium do not reach the urogenital vasculature in mice, and
instead are usually found in the mesenteries in the liver and bowel.
We therefore identified the S. mansoni orthologue of S.
haematobium cystatin (Smp_034420; Figure S2), expressed it in
recombinant form, and tested its vaccine efficacy in a mouse model
of S. mansoni infection. Recombinant S. mansoni cystatin was
insoluble in the absence of chaotropic agents and was therefore
solubilized with 8M urea and purified by nickel-NTA
chromatography under denaturing conditions (not shown). In
two independent trials, vaccination of mice with S. mansoni
cystatin was immunogenic (Figure S3). Significant reductions in
liver egg burdens (45-55%) and intestinal egg burdens (50-54%)
were observed in mice vaccinated with cystatin compared to control
mice vaccinated with E. coli thioredoxin in both trials (Figures
5A–D). Vaccination with cystatin did not, however, result in a
significant difference in adult fluke burdens in either trial (Figures
5E, F). Trial 1 liver eggs: TRX group 19,404 ± SD 4,052 vs. cystatin
10,730 ± 3,652, P = 0.0001; trial 2 liver eggs: TRX group 21,191 ±
5,959 vs. cystatin 9,466 ± 2,215, P = 0.0001). Trial 1 intestinal eggs:
TRX group 14,029 ± 4,530 vs. cystatin 6,484 ± 2,206, P = 0.0002;FIGURE 4 | IgG profiles to arrayed antigens differ between S. haematobium-infected subjects who do and do not acquire resistance 18 months after PZQ
treatment. Average signal intensities depicting IgG responses to each antigen are shown for the CI and DIV cohorts after PZQ treatment. Black arrows denote
antigens which are also the target of significantly higher IgG responses in the DIV cohort after PZQ treatment. The dashed line represents the reactivity cut-off,
determined as the average + 3SD of the IgG response to all arrayed antigens from the non-endemic negative cohort. Significance determined by student’s t-test.
*P ≤ 0.05, **P ≤ 0.01.May 2021 | Volume 12 | Article 663041
Pearson et al. Urogenital Schistosomiasis Vaccinomicstrial 2 intestinal eggs: TRX group 11,204 ± 3,295 vs. cystatin 5,609 ±
1,769, P = 0.0003.DISCUSSION
PZQ is widely used to treat human schistosome infections and
has two main effects on adult flukes - paralysis and tegument
damage. Experimental work in mice has demonstrated
that PZQ treatment exposes tegumental antigens (22, 23), and
studies in disease-endemic areas have shown that repeated
rounds of PZQ therapy results in enhanced Th2 cytokine and
antibody responses, notably IgE against surface membraneFrontiers in Immunology | www.frontiersin.org 8proteins (7, 24). In addition, adult worms and eggs suppress
schistosome-specific immune responses (25) so that worm death
results in increased responsiveness to schistosome antigens.
Only limited research has been conducted on the nature of
DIV, particularly in the post-genomic era. As such, we exploited
various omics datasets to generate the first S. haematobium
proteome array and probed the 1,000 proteins with sera from
DIV and CI individuals to identify antigens that are selective
targets of elevated IgG responses in human subjects after PZQ
therapy. The major target antigens of the DIV response included
a range of secreted, membrane and intracellular proteins sourced
from ES products, EVs, tegument and eggs. While numerous




FIGURE 5 | Vaccination of mice with recombinant S. mansoni cystatin confers protection in the form of significantly reduced liver and intestinal S. mansoni egg
burdens but not adult fluke burdens across two independent trials. (A) liver egg reduction trial 1, (B) liver egg reduction trial 2, (C) intestinal egg reduction trial 1 and
(D) intestinal egg reduction trial 2. The percentage of reductions in parasite burden are above each dataset. Differences between cystatin (smp_034420) vaccinated
group and the control group vaccinated with recombinant thioredoxin (TrX) were analysed with a student’s t-test. ***P < 0.001. Adult fluke burdens did not
significantly differ between vaccinated and control groups in either trial (E, F).May 2021 | Volume 12 | Article 663041
Pearson et al. Urogenital Schistosomiasis Vaccinomicsserum antibody responses after PZQ therapy, we focused on one
in particular, MS3_01693, a member of the cystatin family of
cysteine protease inhibitors. Our rationale for choosing cystatin
was multi-factorial, including (i) elevated antibody titers in DIV
cohort after PZQ treatment compared to CI group, including a
complete absence of detectable antibodies in DIV subjects pre-
treatment (Tables 1 and 2); (ii) absence of existing literature on
cystatin vaccines in flukes but evidence of a protective role for
anti-cystatin antibodies against parasitic nematodes (26, 27) and
blood-feeding ticks (28); (iii) proven role of the Schistosoma
japonicum orthologue in suppressing inflammation.
While not previously reported as anti-schistosome vaccine
antigens, a recombinant form of cystatin from S. japonicum has
immunomodulatory properties and confers protection against a
range of inducible inflammatory diseases in mice (29–32),
possibly via inhibition of antigen presenting cell lysosomal
cysteine protease, thereby interrupting antigen processing and
presentation (33) and macrophage polarization (34). It is feasible
that S . haematobium cys ta t in per forms a s imi lar
immunoregulatory role in urogenital schistosomiasis, and that
vaccine-induced antibodies interrupt its ability to attenuate
inflammation and the development of an anti-schistosome
protective immune response. Indeed, a multivalent subunit
vaccine against a blood-feeding gastrointestinal nematode
parasite of sheep confers upwards of 70% protection against
challenge infection and contains numerous immunomodulatory
ES proteins (35).
A number of other antigens were identified as selective targets
of DIV IgG responses, including MS3_02176, a microsomal
glutathione S-transferase 3 (GST-3). Microsomal GSTs are
membrane -associated proteins primarily involved in the
production of eicosanoids (36), not to be mistaken with
cytosolic GSTs including the S. mansoni 28 kDa GST vaccine
that progressed into late phase clinical trials (37) but is no longer
in clinical development. Little is known about the role of this
family of proteins in parasitic helminths, but given the
importance of leukotrienes and other eicosanoid inflammatory
mediators, this family warrants further attention and should be
the focus of future vaccine trials in animal models.
Antibodies targeting MS3_04279, a member of the saposin
family of pore-forming proteins were 12-fold greater in DIV than
CI subjects post-PZQ treatment. Saposins are known to be
immunogenic in S. mansoni infection (38) and are candidate
serodiagnostic antigens in S. japonicum infection (39).
Recombinant saposins from the liver flukes Fasciola hepatica
and Fasciola gigantica confer protection against challenge
infection in animal models (40, 41). Saposins from the
gastrodermis of S. mansoni were tested as subunit vaccines in
the mouse model and did not confer protection (38), but based
on these findings herein, the S. haematobium proteins should be
tested before final down-selection.
The protein that was the target of the highest-fold change in
DIV IgG responses before and after treatment was
synaptotagmin. The role of this family of proteins has not beenFrontiers in Immunology | www.frontiersin.org 9addressed in parasitic helminths, but in the free-living nematode,
Caenorhabditis elegans, synaptotagmin-1 functions as a calcium-
sensing protein and orchestrates the membrane association/
disassociation cycle of Rab3 in the recruitment of synaptic
vesicles (42). Synaptotagmin was identified in the tegument
proteome of S. haematobium (14), and an important role for
this protein has been described in presynaptic exosome release in
Drosophila (43). It is feasible that like other proteins on the
surface of schistosome EVs (44), antibodies to synaptotagmin
might interrupt fluke vesicle uptake by host vascular endothelial
and immune cells, thereby interrupting an important mechanism
of immunoregulation. It is also possible that synaptotagmin
might be released by dying worms (after PZQ treatment),
thereby driving an immune response that is not meaningful in
terms of protection, and further work is required to shed light on
this issue.
Herein we focused our schistosomiasis vaccine antigen
discovery efforts on the targets of IgG responses. While IgE has
been shown to be an important antibody isotype in the
acquisition of DIV (45), anti-helminth vaccines that induce IgE
pose serious risks for development of serious adverse events,
including allergic reactions (46) and possibly even anaphylaxis.
Current candidate schistosomiasis vaccines confer protection in
animal models and are targets of IgG but not IgE responses in
exposed individuals (18, 47), so the candidate antigens identified
in this study now require screening with sera from infected
subjects to assess their IgE reactivity.
Crosnier and colleagues recently described the expression of
115 S . manson i pro te ins and screened them for
immunoreactivity with sera from human subjects who were
experimentally infected with male parasites (48). However, to
express 1,000 proteins in mammalian cells would require a
Herculean effort and substantial funding and definitely is not
considered high-throughput. The beauty of the system we used is
the high-throughput nature of the immunomics approach where
crude cell-free reverse transcription-translation products are
printed and probed. While some conformational epitopes
might not be faithfully reproduced in this system, the ease with
which large numbers of proteins can be rapidly produced and
screened provides sufficient support for such an approach.
In summary, we used an immunomics based approach to
screen 1,000 S. haematobium proteins to identify those that are
selectively or preferentially recognised by IgG antibodies from
human subjects who developed praziquantel-induced
immunologic resistance to schistosomiasis. Multiple candidate
antigens were identified, and one, cystatin, was validated as a
possible anti-fecundity and potentially transmission-blocking
vaccine by reducing egg output from vaccinated individuals.
Much work remains to further assess different recombinant
production systems, formulations and delivery modes of
cystatin and other promising antigens, including testing their
efficacy in a chemotherapy-linked delivery regimen in a robust
animal model of S. haematobium infection, such as non-
human primates.May 2021 | Volume 12 | Article 663041
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Supplementary Figure 1 | Heatmap showing source of Schistosoma
haematobium antigen targets (rows) of significantly elevated IgG responses in
individual DIV subjects (columns) before (S0) and after (S3) praziquantel treatment.
AES, Adult Excretory/Secretory proteome; EV, Extracellular Vesicle proteome; T,
Tegument proteome; SEA, Soluble Egg Antigen proteome; Sm, bioinformatically
identified homolog/ortholog of S. mansoni protein predicted to be secreted.
Supplementary Figure 2 | Amino acid alignment of Schistosoma. haematobium
(Sh), S. japonicum (Sj) and S. mansoni (Sm) cystatins.
Supplementary Figure 3 | ELISA showing serum IgG response of mice
vaccinated with recombinant Schistosoma mansoni cystatin (smp_034420; trial 1)
prior to immunisation and post-immunisation but prior to challenge infection.REFERENCES
1. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN.
Schistosomiasis. Nat Rev Dis Prim (2018) 4:13. doi: 10.1038/s41572-018-
0013-8
2. King CH, Kittur N, Binder S, Campbell CH, N’Goran EK,Meite A, et al. Impact of
DifferentMass DrugAdministration Strategies for Gaining and Sustaining Control
of SchistosomaMansoni and SchistosomaHaematobium Infection in Africa.Am J
Trop Med Hyg (2020) 103:14–23. doi: 10.4269/ajtmh.19-0829
3. Brindley PJ, Strand M, Norden AP, Sher A. Role of Host Antibody in the
Chemotherapeutic Action of Praziquantel Against Schistosoma Mansoni:
Identification of Target Antigens. Mol Biochem Parasitol (1989) 34:99–108.
doi: 10.1016/0166-6851(89)90001-7
4. Ottesen EA, Hiatt RA, Cheever AW, Sotomayor ZR, Neva FA. The Acquisition
and Loss of Antigen-Specific Cellular Immune Responsiveness in Acute and
Chronic Schistosomiasis in Man. Clin Exp Immunol (1978) 33:37–47.
5. Mohammed ES, Nakamura R, Kalenda YD, Deloer S, Moriyasu T, Tanaka M,
et al. Dynamics of Serological Responses to Defined Recombinant Proteins
During Schistosoma Mansoni Infection in Mice Before and After the
Treatment With Praziquantel. PloS Negl Trop Dis (2020) 14:e0008518.
doi: 10.1371/journal.pntd.0008518
6. Tawfik AF, Carter CE, Colley DG. Effects of Anti-Schistosomal
Chemotherapy on Immune Responses, Protection and Immunity. I.
Changes in Cellular and Humoral Responses. Am J Trop Med Hyg (1986)
35:100–9. doi: 10.4269/ajtmh.1986.35.100
7. Joseph S, Jones FM, Walter K, Fulford AJ, Kimani G, Mwatha JK, et al.
Increases in Human T Helper 2 Cytokine Responses to Schistosoma MansoniWorm and Worm-Tegument Antigens are Induced by Treatment With
Praziquantel. J Infect Dis (2004) 190:835–42. doi: 10.1086/422604
8. Mutapi F, Billingsley PF, Secor WE. Infection and Treatment Immunizations
for Successful Parasite Vaccines. Trends Parasitol (2013) 29:135–41.
doi: 10.1016/j.pt.2013.01.003
9. Hotez PJ, Bottazzi ME, Bethony J, Diemert DD. Advancing the Development
of a Human Schistosomiasis Vaccine. Trends Parasitol (2019) 35:104–8.
doi: 10.1016/j.pt.2018.10.005
10. Davies DH, Molina DM,Wrammert J, Miller J, Hirst S, Mu Y, et al. Proteome-
Wide Analysis of the Serological Response to Vaccinia and Smallpox.
Proteomics (2007) 7:1678–86. doi: 10.1002/pmic.200600926
11. Driguez P, Doolan DL, Loukas A, Felgner PL, McManus DP. Schistosomiasis
Vaccine Discovery Using Immunomics. Parasit Vectors (2010) 3:4.
doi: 10.1186/1756-3305-3-4
12. Liang L, Felgner PL. A Systems Biology Approach for Diagnostic and Vaccine
Antigen Discovery in Tropical Infectious Diseases. Curr Opin Infect Dis
(2015) 28:438–45. doi: 10.1097/QCO.0000000000000193
13. PearsonMS, Becker L, Driguez P, YoungND, Gaze S,Mendes T, et al. OfMonkeys
andMen: Immunomic Profiling of Sera FromHumans and non-Human Primates
Resistant to Schistosomiasis Reveals Novel Potential Vaccine Candidates. Front
Immunol (2015) 6:213. doi: 10.3389/fimmu.2015.00213
14. Sotillo J, Pearson MS, Becker L, Mekonnen GG, Amoahid AS, van Dam G,
et al. In-Depth Proteomic Characterization of Schistosoma Haematobium:
Towards the Development of New Tools for Elimination. PloS Negl Trop Dis
(2019) 13(5):e0007362. doi: 10.1371/journal.pntd.0007362
15. Mekonnen GG, Tedla BA, Pickering D, Becker L, Wang L, Zhan B, et al.
Schistosoma Haematobium Extracellular Vesicle Proteins Confer ProtectionMay 2021 | Volume 12 | Article 663041
Pearson et al. Urogenital Schistosomiasis Vaccinomicsin a Heterologous Model of Schistosomiasis. Vaccines (Basel) (2020) 8(3):416.
doi: 10.3390/vaccines8030416
16. Sotillo J, Pearson M, Becker L, Mulvenna J, Loukas A. A Quantitative
Proteomic Analysis of the Tegumental Proteins From Schistosoma Mansoni
Schistosomula Reveals Novel Potential Therapeutic Targets. Int J Parasitol
(2015) 45:505–16. doi: 10.1016/j.ijpara.2015.03.004
17. de Assis RR, Ludolf F, Nakajima R, Jasinskas A, Oliveira GC, Felgner PL, et al.
A Next-Generation Proteome Array for Schistosoma Mansoni. Int J Parasitol
(2016) 46:411–5. doi: 10.1016/j.ijpara.2016.04.001
18. Gaze S, Driguez P, Pearson MS, Mendes T, Doolan DL, Trieu A, et al. An
Immunomics Approach to Schistosome Antigen Discovery: Antibody
Signatures of Naturally Resistant and Chronically Infected Individuals From
Endemic Areas. PloS Pathog (2014) 10:e1004033. doi: 10.1371/
journal.ppat.1004033
19. Davies DH, Liang X, Hernandez JE, Randall A, Hirst S, Mu Y, et al. Profiling
the Humoral Immune Response to Infection by Using Proteome Microarrays:
High-Throughput Vaccine and Diagnostic Antigen Discovery. Proc Natl Acad
Sci USA (2005) 102:547–52. doi: 10.1073/pnas.0408782102
20. Proietti C, Zakrzewski M, Watkins TS, Berger B, Hasan S, Ratnatunga CN,
et al. Mining, Visualizing and Comparing Multidimensional Biomolecular
Data Using the Genomics Data Miner (Gmine) Web-Server. Sci Rep (2016)
6:38178. doi: 10.1038/srep38178
21. Tedla BA, Pickering D, Becker L, Loukas A, Pearson MS. Vaccination With
Schistosoma Mansoni Cholinesterases Reduces Parasite Burden and Egg
Viability in a Mouse Model of Schistosomiasis. Vaccines (2020) 8(2):162.
doi: 10.3390/vaccines8020162
22. Fallon PG, Cooper RO, Probert AJ, Doenhoff MJ. Immune-Dependent
Chemotherapy of Schistosomiasis. Parasitology (1992) 105(Suppl):S41–8.
doi: 10.1017/s003118200007534x
23. Fallon PG, Doenhoff MJ. Active Immunization of Mice With Schistosoma
Mansoni Worm Membrane Antigens Enhances Efficacy of Praziquantel.
Parasite Immunol (1995) 17:261–8. doi: 10.1111/j.1365-3024.1995.tb01024.x
24. Pinot de Moira A, Jones FM, Wilson S, Tukahebwa E, Fitzsimmons CM,
Mwatha JK, et al. Effects of Treatment on IgE Responses Against Parasite
Allergen-Like Proteins and Immunity to Reinfection in Childhood
Schistosome and Hookworm Coinfections. Infect Immun (2013) 81:23–32.
doi: 10.1128/IAI.00748-12
25. Pearce EJ, MacDonald AS. The Immunobiology of Schistosomiasis. Nat Rev
Immunol (2002) 2:499–511. doi: 10.1038/nri843
26. Arumugam S, Zhan B, Abraham D, Ward D, Lustigman S, Klei TR. Vaccination
With Recombinant Brugia Malayi Cystatin Proteins Alters Worm Migration,
Homing and Final Niche Selection Following a Subcutaneous Challenge of
Mongolian Gerbils (Meriones Unguiculatus) With B. malayi Infect Larvae
Parasit Vectors (2014) 7:43. doi: 10.1186/1756-3305-7-43
27. Liu XD,Wang XL, Bai X, Liu XL,WuXP, Zhao Y, et al. Oral AdministrationWith
Attenuated Salmonella Encoding a Trichinella Cystatin-Like Protein Elicited Host
Immunity. Exp Parasitol (2014) 141:1–11. doi: 10.1016/j.exppara.2014.03.015
28. Kotsyfakis M, Anderson JM, Andersen JF, Calvo E, Francischetti IM, Mather
TN, et al. Cutting Edge: Immunity Against a “Silent” Salivary Antigen of the
Lyme Vector Ixodes Scapularis Impairs its Ability to Feed. J Immunol (2008)
181:5209–12. doi: 10.4049/jimmunol.181.8.5209
29. Gao S, Li H, Xie H, Wu S, Yuan Y, Chu L, et al. Therapeutic Efficacy of
Schistosoma Japonicum Cystatin on Sepsis-Induced Cardiomyopathy in a Mouse
Model. Parasit Vectors (2020) 13:260. doi: 10.1186/s13071-020-04104-3
30. Liu F, Cheng W, Pappoe F, Hu X, Wen H, Luo Q, et al. Schistosoma
Japonicum Cystatin Attenuates Murine Collagen-Induced Arthritis.
Parasitol Res (2016) 115:3795–806. doi: 10.1007/s00436-016-5140-0
31. Wang S, Xie Y, Yang X, Wang X, Yan K, Zhong Z, et al. Therapeutic Potential of
Recombinant Cystatin From Schistosoma Japonicum in TNBS-induced
Experimental Colitis of Mice. Parasit Vectors (2016) 9:6. doi: 10.1186/s13071-
015-1288-1
32. Yan K, Wang B, Zhou H, Luo Q, Shen J, Xu Y, et al. Amelioration of Type 1
Diabetes by Recombinant fructose-1,6-bisphosphate Aldolase and Cystatin
Derived From Schistosoma Japonicum in a Murine Model. Parasitol Res
(2020) 119:203–14. doi: 10.1007/s00436-019-06511-7
33. Chen L, He B, Hou W, He L. Cysteine Protease Inhibitor of Schistosoma
Japonicum - A Parasite-Derived Negative Immunoregulatory Factor. Parasitol
Res (2017) 116:901–8. doi: 10.1007/s00436-016-5363-0Frontiers in Immunology | www.frontiersin.org 1134. Yang X, Liu J, Yue Y, ChenW, Song M, Zhan X, et al. Cloning, Expression and
Characterisation of a Type II Cystatin From Schistosoma Japonicum, Which
Could Regulate Macrophage Activation. Parasitol Res (2014) 113:3985–92.
doi: 10.1007/s00436-014-4064-9
35. Nisbet AJ, McNeilly TN, Wildblood LA, Morrison AA, Bartley DJ, Bartley Y,
et al. Successful Immunization Against a Parasitic Nematode by Vaccination
With Recombinant Proteins. Vaccine (2013) 31:4017–23. doi: 10.1016/
j.vaccine.2013.05.026
36. Thulasingam M, Haeggstrom JZ. Integral Membrane Enzymes in Eicosanoid
Metabolism: Structures, Mechanisms and Inhibitor Design. J Mol Biol (2020)
432:4999–5022. doi: 10.1016/j.jmb.2020.07.020
37. Capron A, Capron M, Dombrowicz D, Riveau G. Vaccine Strategies Against
Schistosomiasis: From Concepts to Clinical Trials. Int Arch Allergy Immunol
(2001) 124:9–15. doi: 10.1159/000053656
38. Don TA, Bethony JM, Loukas A. Saposin-Like Proteins are Expressed in the
Gastrodermis of Schistosoma Mansoni and are Immunogenic in Natural
Infections. Int J Infect Dis (2008) 12(6):e39–47. doi: 10.1016/j.ijid.2007.10.007
39. Liu S, Zhou X, Piao X, Hou N, Shen Y, Zou Y, et al. Saposin-Like Proteins, a
Multigene Family of Schistosoma Species, are Biomarkers for the
Immunodiagnosis of Schistosomiasis Japonica. J Infect Dis (2016) 214:1225–
34. doi: 10.1093/infdis/jiw188
40. Kueakhai P, Changklungmoa N, Waseewiwat P, Thanasinpaiboon T,
Cheukamud W, Chaichanasak P, et al. Characterization and Vaccine
Potential of Fasciola Gigantica Saposin-Like Protein 1 (SAP-1). Vet
Parasitol (2017) 233:115–22. doi: 10.1016/j.vetpar.2016.12.009
41. Rivera F, Espino AM. Adjuvant-Enhanced Antibody and Cellular Responses to
Inclusion Bodies Expressing FhSAP2 Correlates With Protection of Mice to Fasciola
Hepatica. Exp Parasitol (2016) 160:31–8. doi: 10.1016/j.exppara.2015.11.002
42. Cheng Y, Wang J, Wang Y, Ding M. Synaptotagmin 1 Directs Repetitive
Release by Coupling Vesicle Exocytosis to the Rab3 Cycle. Elife (2015) 4:
e05118. doi: 10.7554/eLife.05118
43. Korkut C, Li Y, Koles K, Brewer C, Ashley J, Yoshihara M, et al. Regulation of
Postsynaptic Retrograde Signaling by Presynaptic Exosome Release. Neuron
(2013) 77:1039–46. doi: 10.1016/j.neuron.2013.01.013
44. Kifle DW, Chaiyadet S, Waardenberg AJ, Wise I, Cooper M, Becker L, et al.
Uptake of Schistosoma Mansoni Extracellular Vesicles by Human Endothelial
and Monocytic Cell Lines and Impact on Vascular Endothelial Cell Gene
Expression. Int J Parasitol (2020) 50:685–96. doi: 10.1016/j.ijpara.2020.05.005
45. Woolhouse ME, Hagan P. Seeking the Ghost of Worms Past. Nat Med (1999)
5:1225–7. doi: 10.1038/15169
46. Diemert DJ, Pinto AG, Freire J, Jariwala A, Santiago H, Hamilton RG, et al.
Generalized Urticaria Induced by the Na-ASP-2 Hookworm Vaccine:
Implications for the Development of Vaccines Against Helminths. J Allergy
Clin Immunol (2012) 130:169–76.e6. doi: 10.1016/j.jaci.2012.04.027
47. Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Wolf RF, et al.
Preclinical Prophylactic Efficacy Testing of Sm-p80-based Vaccine in a
Nonhuman Primate Model of Schistosoma Mansoni Infection and
Immunoglobulin G and E Responses to Sm-p80 in Human Serum Samples
From an Area Where Schistosomiasis is Endemic. J Infect Dis (2011)
204:1437–49. doi: 10.1093/infdis/jir545
48. Crosnier C, Hokke CH, Protasio AV, Brandt C, Rinaldi G, Langenberg MCC,
et al. Screening of a Library of Recombinant Schistosoma Mansoni Proteins
With Sera From Murine and Human Controlled Infections Identifies Early
Serological Markers. J Infect Dis (2020) jiaa329. doi: 10.1093/infdis/jiaa329
Conflict of Interest: BG was employed by Ares Trading, S.A.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2021 Pearson, Tedla, Becker, Nakajima, Jasinskas, Mduluza, Mutapi,
Oeuvray, Greco, Sotillo, Felgner and Loukas. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original author(s)
and the copyright owner(s) are credited and that the original publication in this journal is
cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.May 2021 | Volume 12 | Article 663041
